Gilead Sciences Stock (NASDAQ:GILD)
Previous Close
$146.00
52W Range
$93.37 - $157.29
50D Avg
$139.47
200D Avg
$122.03
Market Cap
$180.27B
Avg Vol (3M)
$7.32M
Beta
0.37
Div Yield
$3.16 (2.18%)
GILD Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| Veklury | $911.00M | $1.80B | $2.18B |
| Other Products, Total Other product sales | $799.00M | $889.00M | $859.00M |
| Cell Therapy Products, Total Cell Therapy Product Sales | $2.18B | $2.38B | $2.24B |
| Products, Other HIV | $20.75B | $19.61B | $18.23B |
| Trodelvy | $1.40B | $1.31B | $1.06B |
| Oncology Product | - | - | $2.93B |
| Royalty, Contract, And Other | - | - | $182.00M |
| Product | - | - | $26.93B |
| Hepatitis B Virus / Hepatitis Delta Virus Product | - | - | $1.02B |
Fiscal year ends in Dec 25 | Currency in USD